Modulators of BCL6 for use in a method of treating a cancer or an autoimmune disease
By using PROTACs to degrade BCL6, the compounds effectively target and reduce BCL6 levels in cancer cells, leading to cell death and offering a promising treatment for BCL6-associated diseases.
WO2025059429A1 Publication Date: 2025-03-20BRISTOL MYERS SQUIBB CO
4 Cites 0 Cited by
Patent Information
- Application Number
- PCT/US2024/046564
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-09-14
- Filing Date
- 2024-09-13
- Publication Date
- 2025-03-20
AI Technical Summary
Technical Problem
Current treatments for cancer and autoimmune diseases lack effective methods to target and modulate BCL6, a protein involved in cell proliferation and survival, leading to unchecked cell growth and disease progression.
Method used
Development of compounds that target BCL6 for degradation using proteolysis targeting chimeras (PROTACs), which bring an E3 ubiquitin ligase in proximity to BCL6, marking it for ubiquitination and subsequent degradation by the proteasome.
Benefits of technology
The compounds achieve significant degradation of BCL6, leading to cell cycle arrest, loss of DNA damage repair, and eventual cell death in cancer cells, thereby providing a therapeutic approach for treating BCL6-associated diseases.
✦ Generated by Eureka AI based on patent content.
Abstract
Provided herein are compounds and compositions thereof for modulating BCL6. In some embodiments, the compounds and compositions are provided for treatment of cancer or an autoimmune disease. In some embodiments, the compounds are of Formula (IA):
Need to check novelty before this filing date? Find Prior Art